Skip to main content
Premium Trial:

Request an Annual Quote

Back Up in the UK

AstraZeneca has resumed its COVID-19 vaccine clinical trial in the UK, NPR reports.

AstraZeneca, which developed its candidate vaccine now dubbed AZD1222 with the University of Oxford, halted its trial following a report that a participant in its trial had possibly developed transverse myelitis. The company announced that an independent committee of experts would be looking into the matter and reviewing safety data.

According to the Guardian, the UK Medicines and Healthcare Products Regulatory Agency has now recommended that the trial resume. "In large trials such as this, it is expected that some participants will become unwell and every case must be evaluated to ensure careful assessment of safety," Oxford says in a statement to the Guardian.

NPR notes that the trial has not yet started back up in the US, and AstraZeneca tells NPR it is working with health officials around the world including the US Food and Drug Administration to resume testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.